The Potential Impact of Vaccination on the Dynamics of Dengue Infections
Tóm tắt
Dengue, classified as a ‘neglected topical disease’, is currently regarded globally as the most important mosquito-borne viral disease, which inflicts substantial socioeconomic and health burden in many tropical and subtropical regions of the world. While efforts continue towards developing and improving the efficacy of a tetravalent vaccine to protect individuals against all dengue virus serotypes, the long-term epidemiological impact of vaccination remains elusive. We develop a serotype-specific, vector–host compartmental model to evaluate the effect of vaccination in the presence of antibody-dependent enhancement and cross-protection following recovery from primary infection. Reproducing the reported multi-annual patterns of dengue infection, our model projects that vaccination can dramatically reduce the overall incidence of the disease. However, if the duration of vaccine-induced protection is shorter than the average lifetime of the human population, vaccination can potentially increase the incidence of severe infection of dengue haemorrhagic fever due to the effects of antibody-dependent enhancement. The magnitude and timelines for this increase depend strongly on the efficacy and duration of the vaccine-induced protection. Corresponding to the current estimates of vaccine efficacy, we show that dengue eradication is infeasible using an imperfect vaccine. Furthermore, for a vaccine that induces lifetime protection, a nearly full coverage of infant vaccination is required for dengue elimination. Our findings suggest that other vector control measures may still play a significant role in dengue prevention even when a vaccine with high protection efficacy becomes available.
Tài liệu tham khảo
Bharaj P, Chahar HS, Pandey A, Diddi K, Dar L, Guleria R, Kabra SK, Broor S (2008) Concurrent infections by all four dengue virus serotypes during an outbreak of dengue in 2006 in Delhi, India. Virol J 5(1):1–5. http://www.virologyj.com/content/5/1/1
Capeding MR et al (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384(9951):1358–1365. doi:10.1016/S0140-6736(14)61060-6
Carrington LB, Simmons CP (2014) Human to mosquito transmission of dengue viruses. Front Immun. doi:10.3389/fimmu.2014.00290
Coudeville L, Garnett GP (2012) Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination. PloS one 7(12):e51244. doi:10.1371/journal.pone.0051244
Cummings DAT et al (2005) Dynamic effects of antibody-dependent enhancement on the fitness of viruses. Proc Natl Acad Sci 102(42):15259–15264. doi:10.1073/pnas.0507320102
Diekmann O, Heesterbeek JAP, Metz JAJ (1990) On the definition and computation of the basic reproduction ratio \(R_0\) in models for infectious diseases in heterogeneous populations. J Math Biol 28:365–382
de Castro Medeiros LC, Castilho CAR, Braga C, de Souza WV, Regis L, Monteiro AM (2011) Modeling the dynamic transmission of dengue fever: investigating disease persistence. PLOS Neglect Trop D 5(1):e942. doi:10.1371/journal.pntd.0000942
Diekmann O, Heesterbeek JAP, Robert MG (2010) The construction of next-generation matrices for compartmental epidemic models. J R Soc Interface 7:873–885. doi:10.1098/rsif.2009.0386
Ferguson N, Anderson R, Gupta S (1999) The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens. Proc Natl Acad Sci 96(2):790–794. doi:10.1073/pnas.96.2.790
Ferguson NM, Donnelly CA, Anderson RM (1999) Transmission dynamics and epidemiology of dengue: insights from age-stratified sero-prevalence surveys. Philos Trans R Soc Lond Ser 354(1384):757–768
Gubler DJ, Clark GG (1995) Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Diseases 1(2):55. doi:10.3201/eid0102.952004
Guzman MG et al (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8:S7–S16. doi:10.1038/nrmicro2460
Guzman MG, Kouri G (2002) Dengue: an update. Lancet Infect Dis 2:33–42. doi:10.1016/S1473-3099(01)00171-2
Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60:421–467
Hss AS et al (2013) Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine 31(49):5814–5821. doi:10.1016/j.vaccine.2013.10.013
Lorono-Pino MA et al (1990) Common occurrence of concurrent infections by multiple dengue virus serotypes. Am J Trop Med Hyg 61(5):725–730
Lourenco J, Recker M (2013) Natural, persistent oscillations in a spatial multi-strain disease system with application to dengue. PLoS Comput Biol 9(10):e1003308. doi:10.1371/journal.pcbi.1003308
Otero M et al (2008) A stochastic spatial dynamical model for Aedes aegypti. Bull Math Biol 70:1297–1325. doi:10.1007/s11538-008-9300-y
Pandey A, Medlock J (2014) The introduction of dengue vaccine may temporarily cause large spikes in prevalence. Epidemiol Infect. Available on CJO2014. doi:10.1017/S0950268814001939. Accessed 11 August 2014
Recker M et al (2009) Immunological serotype interactions and their effect on the epidemiological pattern of dengue. Proc R Soc B Biol Sci 276(1667):2541–2548. doi:10.1098/rspb.2009.0331
Reich NG et al (2013) Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface 10:20130414. doi:10.1098/rsif.2013.0414
Thavara U et al (2006) Double infection of heteroserotypes of dengue viruses in field populations of Aedes aegypti and Aedes albopictus (Diptera: Culicidae) and serological features of dengue viruses found in patients in southern Thailand. 37(3):468–476. http://www.ncbi.nlm.nih.gov/pubmed/17120966
Villar L et al (2014) Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. doi:10.1056/NEJMoa1411037. Accessed 8 January 2015
Wallace D, Canouet V, Garbes P, Wartel TA (2013) Challenges in the clinical development of a dengue vaccine. Curr Opin Virol 3(3):352–356. doi:10.1016/j.coviro.2013.05.014
Wearing HJ, Rohani P (2006) Ecological and immunological determinants of dengue epidemics. Proc Natl Acad Sci 103(31):11802–11807. doi:10.1073/pnas.0602960103
Wilder-Smith A et al (2012) DengueTools: innovative tools and strategies for the surveillance and control of dengue. Glob Health Act. doi:10.3402/gha.v5i0.17273
WHO (2014) Dengue and severe dengue. http://www.who.int/mediacentre/factsheets/fs117/en/
WHO (2012) Global strategy for dengue prevention and control 2012–2020. http://www.who.int/immunization/sage/meetings/2013/april/5_Dengue_SAGE_Apr2013_Global_Strategy.pdf